Regulation of food allergy and anaphylaxis by IL 33

IL 33 对食物过敏和过敏反应的调节

基本信息

  • 批准号:
    8694990
  • 负责人:
  • 金额:
    $ 21.02万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-02-11 至 2019-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): IL-33 is a recently discovered member of the IL-1 family of cytokines. Administration of recombinant IL-33 has been shown to have profound effects on a diverse range of diseases, including arthritis, infection and allergy that are mediate though its receptor ST2. Several different cell types have been shown to express IL-33 and we, and others, have shown that epithelial cells have a high constitutive expression and release it during damage. Consequently, IL-33 has been coined an "alarmin", important for the communication between tissue cells and the immune response. However, we have demonstrated that inflammatory cells, such as mast cells [and dendritic cells], have low levels at rest but are induced to express IL-33 upon their activation. The functional consequences of these different sources of IL-33 have not been studied and determining these is the basis for our study. Our preliminary data establishes that ST2 is necessary for both the sensitization to allergens, as well as efficiently mounting an inflammatory response when sensitization in bypassed. Interestingly, our findings show that ST2 is only required for sensitization through the intestine and that, by injecting the same antigen, ST2 KO mice are capable of becoming allergic. We hypothesize that epithelial cells are the necessary source of IL-33 that drives allergic sensitization while mast cell-derived IL-33 is the critical signal for inflammation after sensitization has occurred. We will examine this hypothesis using murine models of food allergy and anaphylaxis that we have developed. Since food allergy is increasing in prevalence and there are very few therapeutic options available at this time, our work has the potential to facilitate new therapies for these patients. We propose to test our hypothesis with two distinct specific aims that address the overall theme of 1) sensitization and 2) elicitation of allergic responses. These aims are: Specific Aim 1: Determine the role of cell-specific IL-33 expression in the generation of peanut-specific antibody and T cell responses. Specific Aim 2: Determine the mechanisms through which IL-33 regulates the generation of tissue inflammation to allergens.
描述(由申请人提供):IL-33是最近发现的IL-1细胞因子家族成员。重组IL-33已被证明对多种疾病有深远的影响,包括关节炎、感染和过敏,这些疾病是通过其受体ST2介导的。几种不同的细胞类型已被证明表达IL-33,我们和其他人已经证明上皮细胞具有高组成表达并在损伤期间释放它。因此,IL-33被认为是一种“警报蛋白”,对组织细胞和免疫反应之间的交流很重要。然而,我们已经证明炎症细胞,如肥大细胞[和树突状细胞],在静止状态下的水平很低,但在它们被激活时被诱导表达IL-33。这些不同来源的IL-33的功能后果尚未研究,确定这些是我们研究的基础。我们的初步数据表明,ST2对于过敏原的致敏以及在绕过致敏时有效地建立炎症反应都是必要的。有趣的是,我们的研究结果表明ST2只需要通过肠道致敏,并且通过注射相同的抗原,ST2 KO小鼠能够变得过敏。我们假设上皮细胞是驱动过敏性致敏的IL-33的必要来源,而肥大细胞来源的IL-33是致敏发生后炎症的关键信号。我们将使用我们开发的食物过敏和过敏反应的小鼠模型来检验这一假设。由于食物过敏的患病率正在上升,而目前可用的治疗选择很少,我们的工作有可能为这些患者提供新的治疗方法。我们建议用两个不同的具体目标来验证我们的假设,以解决1)致敏和2)引发过敏反应的总体主题。这些目标是:特异性目标1:确定细胞特异性IL-33表达在花生特异性抗体和T细胞反应产生中的作用。特异性目的2:确定IL-33调节组织对过敏原炎症产生的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PAUL J BRYCE其他文献

PAUL J BRYCE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PAUL J BRYCE', 18)}}的其他基金

Regulation of Food Allergy and Anaphylaxis by IL-33
IL-33 对食物过敏和过敏反应的调节
  • 批准号:
    8707087
  • 财政年份:
    2013
  • 资助金额:
    $ 21.02万
  • 项目类别:
Regulation and functions of mast cell-derived IL-33
肥大细胞来源的 IL-33 的调节和功能
  • 批准号:
    8308810
  • 财政年份:
    2011
  • 资助金额:
    $ 21.02万
  • 项目类别:
Regulation of T cell migration by histamine
组胺调节 T 细胞迁移
  • 批准号:
    7350662
  • 财政年份:
    2008
  • 资助金额:
    $ 21.02万
  • 项目类别:
Regulation of T cell migration by histamine
组胺调节 T 细胞迁移
  • 批准号:
    7559679
  • 财政年份:
    2008
  • 资助金额:
    $ 21.02万
  • 项目类别:
Regulation of T cell migration by histamine
组胺调节 T 细胞迁移
  • 批准号:
    8212021
  • 财政年份:
    2008
  • 资助金额:
    $ 21.02万
  • 项目类别:
Regulation of Allergic Inflammation by Histamine
组胺调节过敏性炎症
  • 批准号:
    8663826
  • 财政年份:
    2008
  • 资助金额:
    $ 21.02万
  • 项目类别:
A novel murine model of food allergy to peanut or egg
对花生或鸡蛋食物过敏的新型小鼠模型
  • 批准号:
    7451159
  • 财政年份:
    2008
  • 资助金额:
    $ 21.02万
  • 项目类别:
Regulation of T cell migration by histamine
组胺调节 T 细胞迁移
  • 批准号:
    8013048
  • 财政年份:
    2008
  • 资助金额:
    $ 21.02万
  • 项目类别:
Regulation of T cell migration by histamine
组胺调节 T 细胞迁移
  • 批准号:
    7754694
  • 财政年份:
    2008
  • 资助金额:
    $ 21.02万
  • 项目类别:
Regulation of Allergic Inflammation by Histamine
组胺调节过敏性炎症
  • 批准号:
    8577516
  • 财政年份:
    2008
  • 资助金额:
    $ 21.02万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 21.02万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 21.02万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 21.02万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 21.02万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 21.02万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 21.02万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 21.02万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 21.02万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 21.02万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 21.02万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了